Condition: Periprosthetic Joint Infection (PJI) · Sponsor: TenNor Therapeutics Inc.
This is a Phase 1/2, randomized, controlled, open-label, proof-of-concept study to evaluate the safety and tolerability, local and systemic PK profiles of TNP-2092 administered via IA injection on the basis of vancomycin IV and oral antibiotics therapy in participants with early (within 1 month of TKA) or acute hematogenous (within 3 weeks of infectious symptoms) PJI requiring or not requiring DAIR therapy after TKA, or requiring long-term antibiotic suppression therapy for PJI (including PJI occurring after various joint replacements and revision surgeries).
This description comes directly from the study's public registry record.
Li Cao · +86 991-4366553 · xjbone@sina.com
Jing Chen · +86 512 86861979 · jing.chen@tennorx.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Xinjiang Medical University | Ürümqi, Xinjiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06889701